Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHADERM vs AMCINONIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Hypertension,Benign prostatic hyperplasia
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., psoriasis, eczema, contact dermatitis)
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Hepatic via cytochrome P450 (CYP3A4); active metabolites.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted renally.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Approximately 85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Approximately 95–99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water.
Apparent volume of distribution is about 0.14–0.3 L/kg, indicating extensive tissue distribution.
Oral bioavailability is 70-80% due to first-pass metabolism; IM bioavailability is 90-95%.
Topical: Bioavailability is high but variable due to skin barrier; systemic absorption ranges from 0.5% to 2% with intact skin, higher with occlusion or inflamed skin. Intralesional: Complete systemic absorption.
No dose adjustment required for renal impairment.
No adjustment required for topical use. Systemic absorption is minimal.
No dose adjustment required for hepatic impairment.
No adjustment required for topical use. Systemic absorption is minimal.
Safety and efficacy in pediatric patients have not been established.
Use lowest effective dose for shortest duration. Apply sparingly to small areas. Avoid use in children <2 years of age. For children ≥2 years: apply thin film once or twice daily. Limit treatment to 5-7 days.
No specific dose adjustment; use with caution due to potential increased skin fragility.
Use lowest effective dose for shortest duration. Apply sparingly due to thinner skin and increased systemic absorption risk. Avoid use on large areas or under occlusive dressings.
None.
None.
Orthostatic hypotension and syncope, especially with first dose,May cause dizziness, drowsiness, or lightheadedness,Use caution in patients with hepatic impairment,May exacerbate angina or heart failure
Systemic absorption with prolonged use or large areas may cause HPA axis suppression, Cushing's syndrome, or hyperglycemia.,Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections.,Avoid use on face, axillae, or groin unless directed; use caution in patients with impaired skin integrity.,Not recommended for diaper dermatitis or for use under occlusive dressings.
Hypersensitivity to alpha-blockers,History of orthostatic hypotension,Micturition syncope,Severe renal impairment,Concomitant use with PDE-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Hypersensitivity to amcinonide or any component of the formulation.,Untreated bacterial, viral, or fungal infections at the application site.,Topical application for ophthalmic or intravaginal use.
No specific food interactions. However, high-fat meals may increase systemic absorption of topical tretinoin marginally; no dietary restrictions necessary. Avoid excessive vitamin A supplements to reduce risk of hypervitaminosis A.
No known food interactions. Avoid excessive ingestion of corticosteroids systemically, but topical application does not require dietary restrictions.
Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fetal harm; avoid unless benefit outweighs risk.
Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic administration, but the risk with topical application is low due to minimal systemic absorption. However, prolonged or large-area use may increase systemic absorption and potential fetal risk. First trimester: Avoid unless clearly needed. Second and third trimesters: Use with caution, avoiding extensive areas, prolonged use, or occlusive dressings.
Unknown if excreted in human milk; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants.
No data available on excretion into breast milk. Systemic absorption after topical application is minimal but may occur with prolonged or large-area use. Caution should be exercised as a risk to the infant cannot be excluded. Use only if clearly needed and apply to smallest area for shortest duration. M/P ratio: Not established.
Increased plasma volume may reduce drug levels; consider dose adjustment based on therapeutic drug monitoring. No specific dose adjustment established; use lowest effective dose.
No disease-specific pharmacokinetic changes for amcinonide. Dosing adjustments are not generally recommended, but consider using the lowest effective dose, smallest area, and shortest duration to minimize systemic absorption. Avoid occlusive dressings and use on large areas or broken skin due to increased absorption.
ALPHADERM (tretinoin 0.05% cream) is a retinoid used for photoaging and acne. Apply a pea-sized amount to dry skin 30 minutes after cleansing; avoid concomitant use of other topical retinoids or exfoliants to prevent irritation. Initiate therapy every other night to build tolerance. Strict sun protection required: use SPF 30+ daily. May cause initial flare of acne (retinoid 'purging') lasting 2-4 weeks. Contraindicated in pregnancy (FDA Category C).
Amcinonide is a high-potency topical corticosteroid, typically used for short-term treatment of corticosteroid-responsive dermatoses. Due to its potency, it should be applied sparingly and not used under occlusion unless directed. Avoid use on face, groin, or axillae due to increased risk of skin atrophy and systemic absorption. Monitor for local adverse effects such as striae, hypopigmentation, or rosacea-like dermatitis. Systemic absorption can occur with extensive use, particularly in children or when applied to large body surface areas.
Apply a thin layer to affected areas once daily at bedtime, 30 minutes after washing and drying face.,Avoid excessive sun exposure; use broad-spectrum sunscreen and protective clothing.,Do not use with other medicated topical products, including benzoyl peroxide or salicylic acid.,Expect mild redness, peeling, or stinging initially; this usually subsides with continued use.,Notify your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Store at room temperature away from heat and light.
Apply a thin layer to affected skin only; do not use on broken or infected skin unless prescribed.,Wash hands after application unless treating hands.,Do not cover treated area with bandages or plastic wrap unless instructed by your doctor.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use for longer than prescribed; overuse can lead to skin thinning and other side effects.,Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant.
No interactions on record
"Magnesium trisilicate, an antacid, can significantly reduce the oral bioavailability of Amcinonide, a topical corticosteroid, when administered concurrently. The mechanism involves magnesium ions chelating with the corticosteroid or altering gastrointestinal pH, thereby impairing dissolution and absorption of Amcinonide. This interaction may lead to reduced efficacy of Amcinonide therapy, particularly when higher systemic exposure is required for therapeutic effect."
"Concurrent use of topical corticosteroids like Amcinonide and systemic acetylcholinesterase inhibitors such as Pyridostigmine may potentiate adverse effects, particularly electrolyte disturbances and cardiovascular events. Pyridostigmine enhances cholinergic activity, which can lead to increased gastrointestinal motility and bronchial secretions, while Amcinonide's mineralocorticoid activity can cause sodium and water retention, aggravating fluid overload and hypertension. This interaction is clinically significant in patients with myasthenia gravis receiving Pyridostigmine, as corticosteroid-induced hypokalemia may worsen muscle weakness."
"The combination of leflunomide, an immunomodulator that inhibits dihydroorotate dehydrogenase and suppresses lymphocyte proliferation, with amcinonide, a potent topical corticosteroid, may result in additive immunosuppression, increasing the risk of serious infections, including bacterial, viral, fungal, and opportunistic infections. Systemic absorption of topical corticosteroids can occur, especially with prolonged use on large areas, damaged skin, or under occlusive dressings, potentiating adrenal suppression and other systemic corticosteroid effects. Patients receiving both agents require careful monitoring for signs of infection, adrenal insufficiency, and other adverse effects related to enhanced immunosuppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHADERM vs AMCINONIDE, answered by our medical review team.
ALPHADERM is a Topical Corticosteroid that works by Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.. AMCINONIDE is a Topical Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHADERM and AMCINONIDE depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHADERM is: Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of AMCINONIDE is: Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHADERM and AMCINONIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHADERM is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fe. AMCINONIDE is classified as Category C. Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.